Effect of the morphine/heroin vaccine on opioid and non-opioid drug-induced antinociception in mice

Méndez, Susana Barbosa; Matus-Ortega, Maura; Miramontes, Ricardo Hernández; Salazar-Juárez, Alberto

doi:10.1016/j.ejphar.2020.173718

Cited by 5 publications

(3 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The early report of a 6 AM-like hapten known as morphine-6-hemisuccinyl-bovine serum albumin (M-6-H-BSA) was explored 50 years ago by Bonese et al [ 62 ]. Subsequently, Anton et al developed a morphine-tetanus toxoid (M-TT) vaccine, which has shown the capability to elicit a strong and long-lasting immune response against heroin [ 16 ]. A similar vaccine utilizing 6-succinylmorphine conjugated to BSA (M-6-S-BSA) could generate high-titer anti-morphine antibodies with satisfactory specificity [ 17 ].…”

Section: Recent Progress In Anti-drug Vaccine Researchmentioning

confidence: 99%

“…Oxycodone/hydrocodone Oxy(Gly)4-sKLH [11] 6OXY(Gly)4-KLH [12] OXY-dKLH [12] OXY-TT [13] Hydro-TT [13] Fentanyl fentanyl-TT [14] FEN-CRM + dmLT [15] Heroin/morphine M-TT [16] M-6-S-BSA [17] M-KLH [18] KLH-6-SM [19] Nicotine NicVAX [20] Niccine [21] Nic-Qb (NIC002) [22] NanoNicVac [23] FH VLPs [24] Cocaine TA-CD [25,26] dAd5GNE [27] UFMG-VAC-V4N2 [28] Methamphetamine MH6-KLH [29] SMO9-KLH [30] SMA-TT [31]…”

Section: Clinical Trials Animal Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Vaccines to Treat Substance Use Disorders: Current Status and Future Directions

Lu,

Li,

Zheng

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Addiction, particularly in relation to psychostimulants and opioids, persists as a global health crisis with profound social and economic ramifications. Traditional interventions, including medications and behavioral therapies, often encounter limited success due to the chronic and relapsing nature of addictive disorders. Consequently, there is significant interest in the development of innovative therapeutics to counteract the effects of abused substances. In recent years, vaccines have emerged as a novel and promising strategy to tackle addiction. Anti-drug vaccines are designed to stimulate the immune system to produce antibodies that bind to addictive compounds, such as nicotine, cocaine, morphine, methamphetamine, and heroin. These antibodies effectively neutralize the target molecules, preventing them from reaching the brain and eliciting their rewarding effects. By obstructing the rewarding sensations associated with substance use, vaccines aim to reduce cravings and the motivation to engage in drug use. Although anti-drug vaccines hold significant potential, challenges remain in their development and implementation. The reversibility of vaccination and the potential for combining vaccines with other addiction treatments offer promise for improving addiction outcomes. This review provides an overview of anti-drug vaccines, their mechanisms of action, and their potential impact on treatment for substance use disorders. Furthermore, this review summarizes recent advancements in vaccine development for each specific drug, offering insights for the development of more effective and personalized treatments capable of addressing the distinct challenges posed by various abused substances.

show abstract

Section: Recent Progress In Anti-drug Vaccine Researchmentioning

confidence: 99%

Section: Clinical Trials Animal Studiesmentioning

confidence: 99%

Vaccines to Treat Substance Use Disorders: Current Status and Future Directions

Lu,

Li,

Zheng

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…In this sense, our laboratory previously reported the efficacy of the tetanus toxoid-conjugated morphine vaccine. 51–57 The M 6 -TT vaccine was capable of generating high titers of antibodies capable of capturing morphine, heroin, and their metabolites 51 , 52 and reducing heroin- or morphine-induced antinociception, 53 , 55 , 56 self-administration, 51 , 52 and locomotor activity, 54 , 57 in Wistar rats and BALB/c, C57Bl/6 and DBA/2 mice. 54 …”

Section: Introductionmentioning

confidence: 99%

COT-TT vaccine attenuates cocaine-seeking and cocaine-conditioned place preference in rats

Barbosa-Méndez,

Matus-Ortega,

Hernandez-Miramontes

et al. 2024

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

Vaccination active, promising alternative immunological strategy to treat of CUD. Various models of cocaine vaccines have been evaluated in animals and humans with relative success. In this sense, it is necessary to improve or optimize the cocaine vaccines already evaluated. Our laboratory previously reported the efficacy of the tetanus toxoid-conjugated morphine vaccine (M 6 -TT). The M 6 -TT vaccine can generate high titers of antibodies and reduce heroin-induced behavioral effects in rodents. So, it would be plausible to assume that if we modify the M 6 -TT vaccine by changing the hapten and maintaining the rest of the structural elements of the vaccine, we will maintain the properties of the M 6 -TT vaccine (high antibody titers). The objective of this study was to determine whether the antibodies generated by a tetanus toxoid-conjugated cocaine vaccine (COC-TT) can recognize and capture cocaine and decrease the cocaine-induced reinforcing effects. Male Wistar rats were immunized with the COC-TT. A solid-phase antibody-capture ELISA was used to monitor antibody titer responses after each booster dose in vaccinated animals. The study used cocaine self-administration and place-preference testing to evaluate the cocaine-reinforcing effects. The COC-TT vaccine could generate high levels of anti-cocaine antibodies. The antibodies reduced the cocaine self-administration and cocaine place preference. In addition, they decreased the cocaine-induced Fos protein expression. These findings suggest that the COC-TT vaccine generates a robust immunogenic response capable of reducing the reinforcing effects of cocaine, which supports its possible future use in clinical trials in patients with CUD.

show abstract